{"id":2984,"date":"2025-04-09T23:03:35","date_gmt":"2025-04-09T23:03:35","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/04\/09\/fda-generics-medicines-access-hhs-layoffs\/"},"modified":"2025-04-09T23:03:35","modified_gmt":"2025-04-09T23:03:35","slug":"fda-generics-medicines-access-hhs-layoffs","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/04\/09\/fda-generics-medicines-access-hhs-layoffs\/","title":{"rendered":"STAT+: Why the closure of an FDA office may impact generics manufacturers \u2014 and everyday Americans"},"content":{"rendered":"<p>    STAT+: Why the closure of an FDA office may impact generics manufacturers \u2014 and everyday Americans<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Amid the hard-to-follow cutbacks at the U.S. Food and Drug Administration, a little-known but important office was eliminated \u2014 and the implications will be felt not only by drugmakers, but consumers. <\/p>\n<p>The Division of Policy Development in the Office of Generic Drug Policy, which was created more than a decade ago, was responsible for a host of activities that were central to ensuring generic drugs were approved properly for the American market.<\/p>\n<p>Now, though, that goal may be in jeopardy. <\/p>\n<p><a href=\"https:\/\/www.statnews.com\/pharmalot\/2025\/04\/09\/fda-generics-medicines-access-hhs-layoffs\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Ed Silverman<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/pharmalot\/2025\/04\/09\/fda-generics-medicines-access-hhs-layoffs\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Why the closure of an FDA office may impact generics manufacturers \u2014 and everyday Americans Amid the hard-to-follow cutbacks at the U.S. Food and Drug Administration, a little-known but important office was eliminated \u2014 and the implications will be felt not only by drugmakers, but consumers. The Division of Policy Development in the Office [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2182,2146,2155,2153,2151,2180,2152],"tags":[2150],"class_list":["post-2984","post","type-post","status-publish","format-standard","hentry","category-drug-pricing","category-fda","category-pharmaceuticals","category-pharmalot","category-policy","category-public-health","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/2984"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=2984"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/2984\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=2984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=2984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=2984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}